Radiolabelling of lipiodol with generator-produced 188Re for hepatic tumor therapy
References (24)
- et al.
Small hepatocellular carcinoma: a clinicopathological study in thirteen patients
Gastroenterology
(1982) - et al.
Effects of arterial administration of high molecular weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma preliminary report
Eur. J. Cancer Clin. Oncol.
(1983) - et al.
Dosimetry consideration of bone-seeking radionuclides for marrow anlation
Med. Phys.
(1993) - et al.
Availability of Re-188 from a tungsten-188/rhenium-188 generator system for therapeutic applications [abstract]
J. Nucl. Med.
(1987) - et al.
Rhenium-188 for therapeutic applications from an alumina based tungsten-188/Re-188 radionuclide generator
NucCompact-Eur/Am. Commun. Nucl. Med.
(1989) - et al.
A column method for the Lipiodol labeling with yttrium-90
J. Nucl. Med.
(1994) - et al.
The influence of free DTPA on the dose distribution of yttrium-90 radiolabelled antibodies
Int. J. Rad. Appl. Instrum.
(1988) - et al.
In vivo microscopy of the liver after injection of lipiodol into the hepatic artery and portal vein in the rat
Acta Radio.
(1989) - et al.
Selective effects of lipiodolized antitumor agents
J. Surg. Oncol.
(1984) - et al.
Hepatocellular carcinoma in rural southern African blacks
Medicine
(1982)
Treatment of hepatocellular carcinoma by transarterial injection of anticancer agents in iodized oil suspension or of radioactive iodized oil solution
Acta Radiol. Diagn.
Role of surgery in the treatment of primary carcinoma of the liver: a 31-year experience
Br. J. Surg.
Cited by (33)
Improved freeze-dried kit for the preparation of <sup>188</sup>ReN-DEDC/lipiodol for the therapy of unresectable hepatocellular carcinoma
2018, Applied Radiation and IsotopesCitation Excerpt :A number of lipophilic 188Re(V)-oxo complexes have been reported for lipiodol 188Re-labeling following above strategy. Wang et al. reported 188Re-EDTB/lipiodol [EDTB = N,N,N",N"-tetrakis(2-benzymidazolylmethyl)-l,2-ethanediamine] for liver cancer therapy (Wang et al., 1996). However, significant accumulation of activity in lungs and kidneys limited its clinical applications.
Development of 4-hexadecyl-4,7-diaza-1,10-decanedithiol (HDD) kit for the preparation of the liver cancer therapeutic agent Re-188-HDD/lipiodol
2015, Nuclear Medicine and BiologyCitation Excerpt :The concomitantly emitted 155-keV γ photon can be used for imaging and monitoring of the therapeutic efficacy. Lipiodol labeled with 188Re via bifunctional chelating agents has been prepared; however it was found that this approach had drawbacks such as low radiolabeling efficiency, low stability and a complicate procedure for preparation [10,19]. 188Re-4-hexadecyl-2,2,9,9-tetramethyl-4,7-diaza-1,10-decanedithiol (HTDD)/lipiodol was later developed to address these limitations; owing to its high labeling yield and simple preparation, 188Re-HTDD/lipiodol was successfully introduced for clinical application [6,7,20].
Development of acetylated HDD kit for preparation of <sup>188</sup>Re-HDD/lipiodol
2007, Applied Radiation and IsotopesPreparation and biodistribution of rhenium-188 ECD/Lipiodol in rats following hepatic arterial injection
2004, Nuclear Medicine and BiologyEfficacy of Re-188-labelled sulphur colloid on prolongation of survival time in melanoma-bearing animals
2001, Nuclear Medicine and BiologyCitation Excerpt :Rhenium-188 is of interest for a variety of therapeutic applications including radioimmunotherapy [2,3] and use Rhenium-188 aminex microspheres and colloids for potential treatment of rheumatoid arthritis of the synovial joints [23,25] and hepatoma [22,24].
Lipiodol solution of a lipophilic agent, <sup>188</sup>Re-TDD, for the treatment of liver cancer
2001, Nuclear Medicine and Biology